Guardant Health (GH) announced a multi-year collaboration with Merck (MRK), known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity Smart platform. Under the multi-year collaboration agreement, Guardant and Merck aim to: use Guardant’s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck’s global clinical studies, evaluate opportunities to develop novel therapies using Guardant liquid biopsy tests as a companion diagnostic, and partner for global commercialization of drugs and companion diagnostics including in US, Asia-Pacific, UK and EU markets.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Announces Strong 2025 Preliminary Revenue Growth
- Guardant Health price target raised to $120 from $100 at Stifel
- Guardant Health price target raised to $135 from $120 at Mizuho
- Guardant Health price target raised to $130 from $100 at TD Cowen
- RBLX, META, GH, IONS: Cathie Wood Loads Up on Roblox, Trims Meta and Biotech Stocks